Q&A

Business, Coronavirus, Q&A

Q&A: Cannabis Delivery Is in the Spotlight Due to COVID-19. What’s Next?

Cannabis Wire spoke with Jaci Flug, former general counsel for the New York State Liquor Authority, about her new role at alcohol delivery platform Drizly and its cannabis arm Lantern, and Lantern’s president.

Business, Q&A

Q&A: Five Questions for Bruce Linton and Kyle Kingsley

Cannabis Wire caught up with the Canopy Growth founder and former CEO on his decision to join Vireo Health as executive chairman.

Q&A

Q&A: Equity in the Spotlight at Gathering of Cannabis Regulators

Colorado regulator Ashley Kilroy tells Cannabis Wire about how equity was top of mind at the 2019 Marijuana Management Symposium in Denver, and about lessons learned from being first.

Business, Global, Q&A

Q&A: Canadian Securities Exchange director talks global industry with Cannabis Wire

Cannabis Wire co-founder interviews Barrington Miller, CSE director of listed client services, at the ArcView Group’s investor forum.

Q&A

Q&A: Three Questions for Sanjay Gupta on CBD

On Sunday, CNN will air Gupta’s fifth documentary about cannabis as medicine. Cannabis Wire caught up with Gupta to learn more about his thoughts on the so-called CBD craze and forthcoming FDA regulations.

Q&A

Q&A: David Bronner’s New Certification System Aimed at California’s Small Farmers Goes Beyond Organics

As the state works up an almost-organic standard, Brother David’s is backing one that also includes soil health, labor fairness, and community engagement.

Q&A

Q&A: What Does Silicon Valley’s PAX Have Planned in Canada?

Cannabis Wire spoke with PAX’s first general manager for Canada about new markets, shifting consumer preferences, and the opportunities afforded by federal legalization.

Q&A

Q&A: How Clark University Hopes to Prepare Future Cannabis Regulators

“It is our responsibility to bring a legitimate and serious educational response to... an issue that is straining many municipalities, state agencies and police and other public safety officials.”

Q&A, Research

Q&A: Do Competing Cannabis Interests Repackage Opioid Research?

A recent cannabis and opioid study highlighted that “corporate actors” with “deep pockets have substantial ability to promote congenial results, as suffering people are desperate for effective solutions.”

Q&A

The Marijuana Policy Project Helped Bring the US to the Brink of Legalization. Now What?

MPP’s new executive director talks equity, federal legalization, and the organization’s role in the booming, multibillion dollar global cannabis industry.

Congress, Q&A

Q&A: On Cannabis Reform, Tulsi Gabbard Wants to Cut to the Chase

A presidential candidate says ending prohibition is the heart of the matter, and that other reforms, like criminal justice, would follow. She hopes for bipartisan support.

Q&A, Research

Can Cannabis Help Parkinson’s Patients?

Q&A: After a survey shows a hunger for answers among clinicians and patients alike, a foundation gathers experts to chart a research path. Here’s why.

Q&A

The Leader of the DOJ Marijuana Working Group Has a Message for Regulators: Slow Down

In an exclusive interview, US Attorney Billy Williams weighs in on banking, hemp, overproduction, illicit-market diversion—and cannabis regulators who fail to think things out.

New York, Q&A

Cuomo’s Cannabis Plan: An Insider’s Assessment

New York Senator Diane Savino, an architect of the state’s medical-cannabis law, has plenty to say about the governor’s ideas for recreational legalization.

Q&A, Research

A Conversation with Ziva Cooper

The Research Director of UCLA's Cannabis Research Initiative talks opioids, how men and women experience cannabis differently, and Alex Berenson's misrepresentation of cannabis research.

Michigan, Q&A

Q&A: How Michigan’s New Cannabis Business Group Seeks to Steady the Market

Josh Hovey shares the Michigan Cannabis Industry Association’s plans to work with the Democratic administration tasked with bringing medical and recreational use sales above board.